Home / Market News / $SMMT

$SMMT news and market catalysts

The 44 most recent market catalysts affecting $SMMT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

44 catalysts 23 high impact 33 bullish 5 bearish Biotechnology
Nov 18, 2026 Corporate Catalyst Bearish Impact 65
Bernstein Downgrades Summit Therapeutics to Underperform
Bernstein downgraded Summit Therapeutics to 'Underperform' from 'Market Perform' and set a price target of $8.30. This move is significant because it represents a bearish outlook f…
Nov 18, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics Initiates Phase III HARMONi-10 Clinical Trial for Ivonescimab
Summit Therapeutics has initiated its global Phase III HARMONi-10 clinical trial for ivonescimab, a bispecific antibody, in patients with locally advanced, unresectable Stage III N…
Nov 15, 2026 Corporate Catalyst Neutral Impact 95
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Summit Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) for ivonescimab. This means the FDA found deficiencie…
Nov 9, 2026 Corporate Catalyst Neutral Impact 75
Summit Therapeutics Awaits FDA Decision on Ivonescimab for Lung Cancer
Summit Therapeutics has disclosed that it is awaiting an FDA regulatory decision for ivonescimab, a bispecific antibody for advanced NSCLC. This is a critical juncture for the comp…
Nov 4, 2026 Corporate Catalyst Neutral Impact 75
Summit Therapeutics Reports Third Quarter 2026 Financial Results
Summit Therapeutics announced its third-quarter 2026 financial results, but the key highlight was the post-quarter close $2 billion strategic equity investment from AstraZeneca. Th…
Oct 24, 2026 Corporate Catalyst Bullish Impact 55
Summit Therapeutics and Lunit Announce Research Agreement for AI-Powered Tumor Microenvironment Analysis
Summit Therapeutics and Lunit Inc. announced a research agreement to integrate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into Summit's immuno-oncology development prog…
Oct 21, 2026 Corporate Catalyst Bullish Impact 65
Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract Cancer
Summit Therapeutics is collaborating with ECOG-ACRIN for a Phase II/III study (EA2251) of ivonescimab in first-line advanced biliary tract cancer (BTC). This is a significant devel…
Oct 19, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics shares are trading higher after the company announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab.
The initiation of a Phase II clinical trial for ivonescimab is a significant positive catalyst for Summit Therapeutics. Advancing a drug to this stage indicates promising early res…
Oct 5, 2026 Corporate Catalyst Neutral Impact 85
Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock
This announcement is a major positive catalyst for Summit Therapeutics, providing substantial capital for drug development and operations without immediate dilution of common share…
Oct 2, 2026 Corporate Catalyst Bullish Impact 75
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
AstraZeneca and Daiichi Sankyo are entering a clinical collaboration with Summit Therapeutics to evaluate a novel cancer drug combination, Datroway and ivonescimab, beginning with …
Oct 1, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics shares are trading higher after Barclays raised its price target on the stock from $18 to $20.
This headline represents a significant corporate catalyst for Summit Therapeutics. An upward revision in a price target from a reputable institution like Barclays indicates a more …
Sep 30, 2026 Corporate Catalyst Bullish Impact 95
Summit Therapeutics Stock Climbs Wednesday: What's Happening?
Summit Therapeutics secured a transformative $2 billion strategic equity investment from AstraZeneca, alongside a co-funded clinical collaboration for its investigational cancer dr…
Sep 29, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on Summit Therapeutics (SMMT) and raised the price target from $40 to $43. This action signals increased confidence fr…
Sep 29, 2026 Corporate Catalyst Bullish Impact 95
Summit Therapeutics shares are trading higher after AstraZeneca announced it entered into an agreement to invest $2 billion in newly issued equity in the company to accelerate the development of ivonescimab.
The $2 billion investment from AstraZeneca into Summit Therapeutics is a massive vote of confidence in Summit's ivonescimab and its broader pipeline, directly leading to a signific…
Sep 29, 2026 Corporate Catalyst Bullish Impact 95
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
AstraZeneca's $2 billion investment in Summit Therapeutics, acquiring a 12% stake, is a major vote of confidence in Summit's cancer drug, ivonescimab. This capital infusion will si…
Sep 28, 2026 Corporate Catalyst Bullish Impact 95
AstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug Conjugates Across Tumour Types; Summit And AstraZeneca Have Also Entered Into A Clinical Collaboration Agreement To Evaluate Sonesitatug Vedotin In Combination With Ivonescimab
AstraZeneca's $2 billion equity investment in Summit Therapeutics is a substantial financial commitment that will significantly boost Summit's resources for developing Ivonescimab.…
Sep 22, 2026 Corporate Catalyst Neutral Impact 65
Summit Therapeutics Notes That Data From The Phase III HARMONi-GI1 Trial Will Be Presented At The European Society For Medical Oncology Congress, October 23–27
Summit Therapeutics is highlighting the upcoming presentation of Phase III HARMONi-GI1 trial data at ESMO 2026. This matters because the trial, sponsored by Akeso, demonstrated sta…
Sep 15, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Summit Therapeutics announced updated overall survival data from its HARMONi Phase III trial for ivonescimab, a bispecific antibody for EGFR-mutated NSCLC. The key update is the su…
Sep 14, 2026 Corporate Catalyst Bullish Impact 85
Why Is Summit Therapeutics Stock Gaining Monday?
Summit Therapeutics' partner Akeso Inc. released compelling Phase 3 data for ivonescimab, demonstrating superior overall survival compared to Merck's pembrolizumab (Keytruda) in fi…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25
Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics (SMMT) from a 'Hold' to a 'Buy' rating and significantly raised the price target from $15 to $25. This action indicat…
Sep 3, 2026 Corporate Catalyst Bullish Impact 85
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Summit Therapeutics' shares are trading higher after its partner, Akeso Inc., announced that ivonescimab monotherapy showed statistically significant and clinically meaningful over…
Sep 3, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
The filing primarily highlights Summit Therapeutics' significant stock jump due to positive results from its Phase III HARMONi-2 study. This is a crucial development for a biotechn…
Sep 3, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics shares are trading higher after the company announced results from the randomized, double-blind Phase III HARMONi-2 study.
The positive Phase III HARMONi-2 study results for Summit Therapeutics are a major corporate catalyst, directly impacting the company's stock price. Successful late-stage clinical …
Sep 2, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy.
Summit Therapeutics' partner Akeso reported that ivonescimab monotherapy achieved a statistically significant improvement in overall survival compared to pembrolizumab monotherapy …
Aug 26, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
Summit Therapeutics' partner Akeso Inc. released positive topline findings from its Phase 3 HARMONi-GI1 clinical trial for ivonescimab, showing statistically significant and clinic…
Aug 26, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics shares are trading higher after the company announced topline results from the randomized Phase III HARMONi-GI1 study met the key secondary endpoints of progression-free survival and objective response rate.
This headline represents a major positive corporate catalyst for Summit Therapeutics. Successful Phase III trial results, especially meeting key secondary endpoints like progressio…
Aug 25, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORR
Summit Therapeutics announced that its partner, Akeso Inc., reported positive topline results from the Phase III HARMONi-GI1 study for ivonescimab in advanced biliary tract cancer.…
Aug 25, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients
Summit Therapeutics' announcement of positive Phase 3 HARMONi trial results for ivonescimab is a significant development. The drug demonstrated a statistically significant improvem…
Aug 25, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics shares are trading higher after the company announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. Bernstein upgraded the stock from Underperform to Market Perform and raised its price target from $9.8 to $11.9.
This headline represents a significant corporate catalyst for Summit Therapeutics. The publication of primary analysis results from a global Phase III clinical trial in a highly re…
Aug 25, 2026 Corporate Catalyst Bullish Impact 65
Bernstein Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $11.9
Bernstein analyst Jeffrey Walch upgraded Summit Therapeutics (SMMT) from 'Underperform' to 'Market Perform' and raised the price target from $9.8 to $11.9. This upgrade signals a m…
Aug 25, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics Announces Publication Of Primary Analysis Results From Global Phase III HARMONi Clinical Trial In The Lancet Oncology
Summit Therapeutics announced the publication of the primary analysis results from its global Phase III HARMONi clinical trial in The Lancet Oncology. This is a significant event b…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
Leerink Partners Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $13
Leerink Partners analyst Daina Graybosch upgraded Summit Therapeutics (SMMT) from an 'Underperform' rating to 'Market Perform' and simultaneously raised the price target from $12 t…
Aug 12, 2026 Corporate Catalyst Bullish Impact 75
Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy
The third NMPA approval for Ivonescimab in China, specifically for first-line advanced squamous NSCLC with chemotherapy, is a significant positive for both Summit Therapeutics and …
Aug 5, 2026 Corporate Catalyst Bullish Impact 65
Summit Therapeutics Expands Its Clinical Development Program For Ivonescimab Into Urothelial Carcinoma An Orbladder Cancer, With The Initiation Of The Global, Multi-Regional Phase II/III HARMONi-GU1 Trial
Summit Therapeutics has announced the initiation of the HARMONi-GU1 trial, a global Phase II/III study for ivonescimab in urothelial carcinoma. This is significant because it expan…
Jul 24, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics' 8-K filing reveals a critical 'going concern' warning, stating that its current cash reserves are inadequate for the next 12 months, despite raising over $299 …
Jul 24, 2026 Corporate Catalyst Bearish Impact 95
Summit Therapeutics shares are trading lower after the company reported Q2 financial results and disclosed it does not have sufficient working capital to fund planned operations for the next twelve months.
This headline represents a major corporate catalyst for Summit Therapeutics, indicating a severe financial distress that directly impacts its 'going concern' status. The lack of su…
Jul 23, 2026 Corporate Catalyst Neutral Impact 75
Summit Therapeutics Plans To Offer $380M Common Shares
Summit Therapeutics has filed an 8-K indicating its plan to offer $380 million in common shares. This is a significant capital raise for a company of its size, likely aimed at fund…
Jul 23, 2026 Corporate Catalyst Bearish Impact 95
Summit Therapeutics shares are trading lower after the company reported Q2 financial results and disclosed it does not have sufficient working capital to fund planned operations for the next twelve months.
This headline signals a severe corporate catalyst for Summit Therapeutics, indicating a significant financial distress. The disclosure of insufficient working capital to fund opera…
Jul 23, 2026 Corporate Catalyst Bearish Impact 95
Summit Therapeutics Raises Going Concern Doubt, Says Current Cash Is Insufficient To Fund Operations For The Next 12 Months
Summit Therapeutics has explicitly stated that its current financial resources are inadequate to sustain operations for the next year, leading to a 'going concern' qualification. T…
Jul 23, 2026 Corporate Catalyst Bearish Impact 92
Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) Estimate
Summit Therapeutics announced its Q2 adjusted EPS of $(0.19), which significantly beat the analyst consensus estimate of $(0.28). This indicates that the company's financial perfor…
Jul 22, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
Summit Therapeutics released updated overall survival data for its lead cancer drug, ivonescimab, from the Phase 3 HARMONi study. The extended follow-up revealed a stronger hazard …
Jul 22, 2026 Corporate Catalyst Bullish Impact 92
Summit Therapeutics shares are trading higher after the company announced Phase III HARMONi clinical trial results.
The positive Phase III HARMONi clinical trial results for Summit Therapeutics are a major corporate catalyst, directly impacting the company's stock price positively. Successful Ph…
Jul 22, 2026 Corporate Catalyst Bullish Impact 85
Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14
Summit Therapeutics announced updated overall survival (OS) data from its Phase III HARMONi trial for ivonescimab, showing an improved hazard ratio of 0.76, consistent across Asian…
Jul 14, 2026 Corporate Catalyst Bullish Impact 65
Summit Therapeutics Signs Agreement With Biossil For Sale Of Ridinilazole, Investigational Phase III Precision Antibiotic Owned By Summit
Summit Therapeutics announced the sale of ridinilazole, an investigational Phase III antibiotic, to Biossil, Inc. This matters because ridinilazole previously failed to meet its pr…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.